Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
A Randomized, Open-label, Multicenter Phase 3 Study of SKB264 Versus Treatment of Physician's Choice (TPC) in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer Who Had Failed at Least One Line of Chemotherapy
Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Listed as NCT06081959, this PHASE3 trial focuses on Metastatic Breast Cancer and remains actively recruiting participants. Sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., it has been updated 5 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
5 versions recorded-
Jan 2026 — Present [monthly]
Recruiting PHASE3
-
Jan 2025 — Jan 2026 [monthly]
Recruiting PHASE3
-
Sep 2024 — Jan 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Nov 2023 — Jul 2024 [monthly]
Not Yet Recruiting PHASE3
First recorded
Oct 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .